文献速递甲状腺疾病

靶向MYC作为未分化甲状腺癌的治疗干预

Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究在四种未分化甲状腺癌细胞系及异种移植模型中评估JQ1的疗效,发现JQ1通过抑制MYC、升高p21和p27、降低磷酸化Rb并阻滞G0/G1向S期进程来抑制增殖,并通过减弱上皮-间质转化信号阻断侵袭;异种移植研究进一步证实JQ1通过抑制p21-细胞周期蛋白/细胞周期蛋白依赖性激酶-Rb-E2F信号抑制肿瘤大小和生长速率。作者认为靶向MYC蛋白可能是有效治疗选择有限的人未分化甲状腺癌的潜在治疗方式。

要点

  • JQ1通过抑制MYC并升高p21和p27,降低磷酸化Rb,延迟细胞周期从G0/G1期向S期进展,从而明显抑制四种未分化甲状腺癌细胞系的增殖。
  • JQ1通过减弱上皮-间质转化信号阻断细胞侵袭。
  • 异种移植研究证实JQ1通过抑制p21-细胞周期蛋白/细胞周期蛋白依赖性激酶-Rb-E2F信号抑制肿瘤大小和生长速率。

核心结论

  • 这些结果提示靶向MYC蛋白可能是有效治疗选择有限的人未分化甲状腺癌的潜在治疗方式。

研究设计与样本

  • 研究在未分化甲状腺癌细胞系和异种移植模型中评估JQ1的疗效,并确定JQ1影响肿瘤细胞增殖和侵袭的关键调控因子。

主要发现

  • JQ1通过抑制MYC并升高p21和p27,降低磷酸化Rb,延迟细胞周期从G0/G1期向S期进展,从而明显抑制四种未分化甲状腺癌细胞系的增殖。
  • JQ1通过减弱上皮-间质转化信号阻断细胞侵袭。
  • 异种移植研究中,JQ1通过抑制p21-细胞周期蛋白/细胞周期蛋白依赖性激酶-Rb-E2F信号抑制肿瘤大小和生长速率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recent studies showed that transcription of the MYC gene is driven by the interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. JQ1, a potent inhibitor that effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. The role of MYC in human ATC and whether JQ1 can effectively target MYC as a treatment modality have not been elucidated. OBJECTIVE: To understand the underlying molecular mechanisms of JQ1, we evaluated its efficacy in human ATC cell lines and xenograft models. DESIGN: We determined the effects of JQ1 on proliferation and invasion in cell lines and xenograft tumors. We identified key regulators critical for JQ1-affected proliferation and invasion of tumor cells. RESULTS: JQ1 markedly inhibited proliferation of four ATC cell lines by suppression of MYC and elevation of p21and p27 to decrease phosphorylated Rb and delay cell cycle progression from the G0/G1 phase to the S phase. JQ1 blocked cell invasion by attenuating epithelial-mesenchymal transition signals. These cell-based studies were further confirmed in xenograft studies in which the size and rate of tumor growth were inhibited by JQ1 via inhibition of p21-cyclin/cyclin-dependent kinase-Rb-E2F signaling. CONCLUSIONS: These results suggest targeting of the MYC protein could be a potential treatment modality for human ATC for which effective treatment options are limited.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Enomoto K, Zhu X, Park S, et al. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017. PMID: 28368473. doi:10.1210/jc.2016-3771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。